03 October 2023 Tapestri AML MRD Pipeline v1.0.1

  • Updated

Through a seamlessly integrated workflow, the assay allows clinician-researchers to:

  • Distinguish true MRD from pre-leukemic or precursor clones with a limit of detection of 0.01%,
  • Reveal clonal architecture (co-occurrence and zygosity of mutation) and uncover the order of acquisition of mutations (phylogeny),
  • Track clonal dynamics and immunophenotypic drifts through disease course to identify therapeutic targets and therapy-resistance subclones.
  • Generate analysis ready reports for single as well as time course analysis using the new MRD AML software.
  • Multiplex up to three samples based on different genotype profiles, the pipeline will demultiplex and produce the MRD reports for each.
Share this article:

Was this article helpful?

0 out of 0 found this helpful

Have more questions? Submit a request